Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy

Area of Science:

• Cardiology
• Oncology
• Pharmacology

Background:

• High-dose chemotherapy (HDC) poses risks of cardiac toxicity.
• Cardiac dysfunction after HDC can manifest late, necessitating early detection markers.
• Identifying early indicators of myocardial injury is crucial for managing HDC-related cardiotoxicity.

Purpose of the Study:

• To investigate the role of cardiac troponin I (cTnI) as an early marker of myocardial injury in patients undergoing HDC.
• To determine if cTnI levels can predict late left ventricular ejection fraction (LVEF) impairment following HDC.
• To assess the clinical and prognostic implications of cTnI elevation in this patient population.

Main Methods:

• Measured plasma cTnI concentrations in 204 cancer patients undergoing HDC.
• Classified patients into troponin-positive (cTnI > 0.4 ng/ml) and troponin-negative groups.
• Monitored LVEF using echocardiography for seven months post-HDC.

Main Results:

• Troponin-negative patients showed transient LVEF reduction post-HDC.
• Troponin-positive patients experienced more significant and persistent LVEF reduction.
• A strong correlation was observed between short-term cTnI increase and maximal LVEF reduction (r = -0.87, p<0.0001) in cTnI+ patients.

Conclusions:

• Elevated cTnI levels accurately predict future LVEF depression in patients receiving HDC for aggressive malignancies.
• cTnI serves as a sensitive and reliable biomarker for acute, minor myocardial damage.
• cTnI monitoring has significant clinical and prognostic value in managing HDC-induced cardiotoxicity.